Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): final update (30-month) of the pivotal ERIVANCE BCC study

¹Dermatology, Mayo Clinic, Scottsdale, AZ, USA²The University of Texas MD Anderson Cancer Center, Houston, TX, USA³Hôpital Saint-Louis, Paris, France⁴Universitätsklinikum Tübingen, Tübingen, Germany⁵Universitätsklinikum Würzburg, Würzburg, Germany⁶University of Michigan, Ann Arbor, MI, USA⁷University of Pennsylvania Medical Center, Philadelphia, PA, USA⁸Hôpital Claude Huriez, Lille, France⁹Premier Specialists, University of New South Wales, Sydney, NSW, Australia¹⁰The Angeles Clinic and Research Institute, Los Angeles, CA, USA¹¹Mayo Clinic Rochester, Rochester, MN, USA¹²Genentech, Inc., South San Francisco, CA, USA¹³Universitätsklinikum Essen, Essen, Germany